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Abstract: Alzheimer’s disease (AD) is an important and rapidly expanding public health 
problem. Its large economic burden is a result of its disabling nature, chronicity, and high 
prevalence in older segments of the population. Current treatments of AD have been criticized 
for providing insufﬁ  cient beneﬁ  t to justify their costs, but variability in assessing both costs and 
beneﬁ  ts make evaluation of the existing data problematic. Inclusion of the value of caregiver 
time is a major driver of the determination of cost-effectiveness. Population-based studies and 
those based on application of economic models to other study outcomes tend to identify greater 
cost-effectiveness than prospectively collected data. Differences in healthcare economics across 
countries also limit generalization of speciﬁ  c study ﬁ  ndings. The current state of evidence sug-
gests that treatment decisions in AD should be based on assessment of beneﬁ  t in individual 
patients rather than broader societal economic factors.
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The cost-effectiveness of treatments for Alzheimer’s disease (AD) is an important 
but controversial topic. The importance derives from both the economic and public 
health perspectives. The prevalence of dementia, a majority of which is attributable to 
AD, is near 25 million cases worldwide and is expected to double every twenty years, 
reaching over 80 million cases by 2040 (Ferri et al 2005). Dementia affects up to 10% 
of the population over age 65 and almost half of those over age 85 (Evans et al 1989), 
but most estimates peak at about one-third of the over 85 group. Nonetheless, nearly 
one in 10 adults over age 85 can be expected to develop a new case of dementia each 
year (Aevarsson and Skoog 1996), and this cohort of the oldest old is the most rapidly 
growing age segment of the population in the world.
The costs associated with this uniformly disabling condition are immense, estimated 
at over US$315 billion worldwide in 2005 (Wimo et al 2007). Developed nations 
account for 73% of the spending, but only 46% of prevalent cases live in those coun-
tries. Dementia is third most expensive illness in the US, with dementia-related costs 
rivaling those for cancer and exceeding diabetes mellitus.
Numerous factors underlie the high costs. By deﬁ  nitions intrinsic to its diagnostic 
criteria, dementia is disabling; this requires others to provide services to the person with 
dementia. These services have economic value, in part attributable to reduced workforce 
productivity among those providing care to family members with dementia. In 2002, 
the incremental annual cost to US businesses associated with family caregiving for 
people with AD was $36.5 billion (Koppel 2002). Dementia is also a chronic disease. 
Average survival after diagnosis exceeds ﬁ  ve years, leading to a prolonged period of 
increasing disability. Finally, individuals with dementia generate 25%–50% higher 
costs in the care of their other conditions, like heart failure and diabetes, than matched 
cases without dementia (Hill et al 2002). The changing demographics of society will Neuropsychiatric Disease and Treatment 2008:4(3) 550
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result in much higher numbers of the older adults at higher 
risk over the next several decades. Cost-effective therapies 
for AD are therefore a public health priority.
There are several ways of considering cost and beneﬁ  t of 
therapeutic approaches. “Cost-effectiveness” centers on the 
relationship between the resources consumed and speciﬁ  ed 
health-related beneﬁ  ts, and allows comparison between two 
interventions or between intervening and not intervening on a 
condition (Neumann et al 2000). Such analyses are not struc-
tured to assess whether it is more effective to intervene on one 
condition in comparison to another. This approach differs from 
“cost-beneﬁ  t” analyses, in which the outcome is considered is 
monetary units, rather than health-oriented issues like length, 
or quality, of life. Guidelines for cost-effectiveness studies 
have been developed to improve the usefulness and consis-
tency of the research; those guidelines recommend inclusion 
of time spent in providing care as an important contributor to 
costs and emphasize the concept of quality-adjusted life years 
as a useful measure to incorporate quality of life and survival 
in a single outcome (Siegel et al 1997).
This article is not intended as a comprehensive, systematic, 
review of costs and beneﬁ  ts in AD treatment. Rather, it is a 
brief overview of pertinent issues that complicate the inter-
pretation of reports regarding costs and potential economic 
beneﬁ  ts of antidementia therapies, highlighting results from 
analysis of prospectively collected and community usage data, 
and touching upon different types of analysis and their impli-
cations. The reader is directed to recent systematic reviews of 
economic aspects of cholinesterase inhibitors (Wimo 2004) and 
memantine (Plosker and Lyseng-Williamson 2005) for more 
comprehensive discussions of this complicated literature.
Differing perspectives on measuring 
cost
Despite its potential importance to individuals and society, 
the cost-effectiveness of antidementia therapy remains con-
troversial. The origins of the controversy lie in difﬁ  culties 
with both measuring cost and assigning value to beneﬁ  t. A 
key issue in measuring cost is the perspective of who is con-
ducting or interpreting the measurement. From the viewpoint 
of an economist, treatment impact on all costs – including 
things like potential losses of workforce productivity – might 
be appropriate for inclusion in assessment of the therapy. 
For a payer of healthcare, whether private insurer or public 
agency, consideration of only those costs covered by the 
insured’s policy is most important.
For informal care costs, individual family members of the 
person with dementia may value their time differently and 
have different thresholds of willingness to expend monetary 
assets. A common example of these differences is the retired 
spouse of a patient being more willing to invest his or her 
own time in care (rather than paying for outside services) 
compared with the employed adult child who is more likely to 
purchase services in order to preserve employment for reasons 
of income, noncash tangible beneﬁ  ts like health insurance, and 
intangibles like self-esteem. Variability in monetary valuation 
of caregiver time is a crucial, and often ignored, aspect of 
estimates of cost-effectiveness of AD treatments.
Many spousal caregivers attribute a low value to their time. 
They may perceive time invested in caring as “given” not 
“taken,” view time in post-retirement life as lacking monetary 
value, or especially in the case of life-long homemakers, view 
care provision as part of an ongoing and never-compensated 
task. In contrast, adult children providing care to AD patients 
may lose work hours and forego higher income employment 
opportunities to provide care. These potential losses correlate 
with the patient’s disease severity, and might be reduced by 
interventions that maintain independence longer (Small et al 
2002). Since each of these interested parties – society, insur-
ers, and family members – measure cost differently, it should 
not be surprising that interpretations of cost-effectiveness vary 
considerably across the published studies.
Another problem in deﬁ  ning cost is the underrecognition and 
undercoding of dementia. While epidemiologic studies predict 
large numbers of dementia cases in the population, insurance 
claims data suggested that a signiﬁ  cant proportion – perhaps 
70%–90% – of dementia cases was not being recognized by 
health insurers because they were not being assigned appropri-
ate diagnostic codes by medical practitioners (Gutterman et al 
1999). The historic magnitude of the underrecognition and 
undercoding problem in the US is illustrated by the study of 
Callahan and colleagues (1995), which noted that – at a Univer-
sity-based Family Medicine clinic – only 25% of patients found 
to express moderate and severe levels of cognitive impairment 
had any notation of the deﬁ  cits in the medical chart. These ﬁ  g-
ures suggest that many older estimates of the economic burden 
of dementia care may be falsely low. More recent Medicare 
claims data identify diagnostic coding rates for dementia that 
more closely approximate epidemiologic predictions (Hill et al 
2002). The availability of approved therapeutic options for AD 
is likely to contribute to the improve rates of diagnosis.
The problem of deﬁ  ning 
effectiveness
The second crucial problem in deﬁ  ning cost-effectiveness 
in dementia is a lack of consensus on what constitutes an Neuropsychiatric Disease and Treatment 2008:4(3) 551
Cost-effectiveness of alzheimer drug therapy
appropriate level of beneﬁ  t from treatment. To comply with 
the requirements of regulatory authorities, most early clinical 
trials focused on cognitive measures and clinicians’ global 
impressions to deﬁ  ne efﬁ  cacy and did not collect direct eco-
nomic measures. Only more recently have trials been planned 
and conducted with economic outcomes. Even so, AD clinical 
trials have been criticized for enrolling populations of “pure” 
AD patients that do not reﬂ  ect the typical comorbidities 
associated with an older population. As a result, incremental 
beneﬁ  t in study samples may not generalize to real-world 
populations. It is also justiﬁ  able to assume that families who 
enroll their loved ones in clinical trials are not representative 
of the caregiving population as a whole. Other problems with 
adapting trials results on cognition to economic outcomes are 
the relatively short duration of clinical trials in comparison 
to the course of disease, nonlinear progression of AD sever-
ity within and across individuals, and limitations in testing 
cognition in more severely demented individuals.
One of the biggest difﬁ  culties in assessing the potential 
impact of dementia treatments is the determination of beneﬁ  t 
in quality of life. Anosognosia (organic unawareness of deﬁ  -
cits) is a common symptom in AD, such that many patients 
become unreliable reporters of their own quality of life. They 
may literally “not know” that they are impaired, and report 
their self-perceived quality of life as quite high. This is in 
distinct contrast their family members’ proxy attributions of 
their quality of life (Naglie et al 2006) and very likely different 
from their premorbid predictions of quality of life in dementia. 
Also, the impact of dementia on overall family quality of life 
is generally not well addressed in dementia, though this is 
measured in other populations like pediatrics and adults with 
developmental disabilities. As a result, there has been no well-
validated or uniformly accepted measure of quality of life in 
dementia through most of the modern therapeutic era.
Assignment of quality of life is especially important in 
economic analyses of treatment effectiveness because of the 
use of  “cost-utility” analyses by payer agencies like the UK’s 
National Health Service (Green et al 2005). The basis of 
cost-utility analysis is a unit known as the “Quality Adjusted 
Life Years” (QALYs). The QALY allows incorporation of 
both patient preferences for different outcomes and reduced 
long term morbidity and mortality associated with treatment 
(Neumann et al 2000). It is based on a scale of 1.0 (perfect) 
to 0.0 (dead). The QALY scale assumes that there is noth-
ing worse than death, but since AD is ranked as one of the 
most feared illnesses among older adults, this may not be a 
valid assumption in dementia. There are relatively few data 
available on the meaningfulness of current QALY estimates 
for dementia, and even those have been subject to widely 
different interpretations (Neumann, 2005).
Prospective studies
Although economists often employ statistical and inferen-
tial models to assess costs and beneﬁ  t, clinical medicine is 
generally more comfortable with directly collected data as 
evidence. Unfortunately, relatively few studies have collected 
prospective data on cost-related issues in AD. It is important 
to note that, even among those that have, many of the cost 
assignments are estimates based on investigator-assigned 
valuation of services rather than actual expenditures.
Secondary economic analyses were conducted as part of 
a standard efﬁ  cacy trial of donepezil vs placebo of 1-year 
duration which enrolled mild to moderately impaired AD 
patients (Mean MMSE = 19). The study was conducted in 
several northern European countries. Accounting for patient 
costs alone, there was a net increase in costs of care estimated 
at US$291 per patient. Reduced use of social services was 
observed and valued at US$1158, but this was more than off-
set by the cost of drug and increased use of medical services. 
Caregiver costs were reduced in all domains except caregiver 
use of emergency department services, resulting in an average 
annualized savings of US$1388. The large majority of these 
savings were attributable to reduced time in direct patient 
care. The authors concluded that the total cost of care for 
patients with mild to moderate AD and their caregivers was 
$1,097 less per patient among the donepezil-treated group 
(Wimo et al 2003a). Obviously, minor differences in the 
valuation of caregiver time could exaggerate or eliminate 
this margin of beneﬁ  t.
Economic outcomes were also prospectively collected as 
part of a long-term double-blind placebo controlled trial of 
donepezil vs placebo among mild and moderately impaired 
AD patients in the UK (Mean MMSE = 19). This is com-
monly referred to as the AD2000 study (AD2000, 2004). 
Despite statistically signiﬁ  cant effects in favor of donepezil 
on cognitive and functional measures, the investigators 
identiﬁ  ed that donepezil treatment was associated with a GB 
£498 increase in overall costs relative to placebo (exclusive 
of costs attributable to donepezil and institutionalization). No 
differences in rates of nursing home placement, behavioral 
symptoms, or caregiver health outcomes were identiﬁ  ed. 
The authors concluded that “donepezil is not cost-effective” 
with effectiveness deﬁ  ned as cost neutrality or better, or, as 
prolonged time to disability. Caregiver time was not included 
as a variable in the economic analysis because measures of 
caregiver time input did not differ between treatment groups. Neuropsychiatric Disease and Treatment 2008:4(3) 552
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The validity of this exclusion is questionable, however, 
since numerous other economic measures also did not 
differ by group and were included in the analysis for cost-
effectiveness. Several other factors also limit the interpreta-
tion and generalizability of the AD2000 ﬁ  ndings. Though 
intended to provide a closer reﬂ  ection of typical clinical 
practice than most trials, this study used an unconventional 
and complicated methodology that makes comparison to 
other studies infeasible (Birks 2006). The trial suffered from 
serious levels of under-enrollment, with less than one-tenth 
of its intended sample completing one year of treatment. 
Finally, the study was conducted in a restricted geographical 
area, the West Midlands of England. It is unknown whether 
dementia-related health care practices there are representative 
of other regions or countries. This issue is important because, 
differences in baseline care practices have inﬂ  uenced other 
economic analyses (Feldman et al 2004).
Overall costs increase with worsening dementia sever-
ity (Langa et al 2001; Small et al 2002; Zhu et al 2006). 
Therefore, studies of cost-effectiveness in samples with more 
advanced dementia are justiﬁ  ed. A randomized double-blind, 
placebo controlled trial of donepezil in moderate to severe 
AD patients conducted at 32 sites (22 Canadian, 6 Austra-
lian, 4 French) included prospectively-collected cost data 
using a “utilization of services” questionnaire and estimates 
of time spent in caregiving (Feldman et al 2004). As with 
studies in milder patients, direct patient care costs were not 
reduced by donepezil therapy, but reductions in caregiver 
time investment were calculated to provide a societal cost 
beneﬁ  t of US$224 over a six month period. The diversity of 
centers involved in this study proved to be important since 
baseline cost estimates (and therefore relative value of the 
intervention) differed signiﬁ  cantly by country, which rein-
forces the possibility that the AD2000 conclusions may not 
prove generalizable.
Memantine was approved for use in the European Union 
in 2002 and in US in 2003; it is indicated for use in moder-
ate and severe stages of dementia. Cost data regarding its 
usage were prospectively collected at 30 US trial sites, using 
the Resource Utilization in Dementia instrument, as part of 
a 7-month double-blind placebo-controlled trial of moder-
ate-to-severely impaired AD patients (Mean MMSE = 11) 
(Wimo et al 2003b). As with studies of donepezil, individual 
patient costs were not reduced by treatment, but the valuation 
assigned to caregiver time led the authors to conclude that 
memantine therapy was associated with a reduction in societal 
costs of ~US$1090 per month. This is a much larger cost ben-
eﬁ  t compared to other studies. The difference is attributable to 
using Bureau of Labor statistics that provide for hourly rates 
of US$9.18–$23.65 depending on factors like age and gender 
of the caregiver. In contrast, the caregiver time was valued 
at only US$4.36/hour in the study of donepezil in moderate 
and severe patients (Feldman et al 2004).
Population studies
Only a few studies have examined the impact of antidementia 
drugs on healthcare costs in clinical practice settings. In an 
early study of this type, a longitudinal survey of caregivers 
of patients with AD reported direct medical expenses in 
108 patients receiving donepezil over 6 months of care and 
compared them with costs of care among 268 control patients 
matched on demographic and clinical variables (Small et al 
1998). No signiﬁ  cant differences were found in mean direct 
medical expenses between groups. Although patients receiv-
ing donepezil had higher expenditures for prescription drugs, 
a nonsigniﬁ  cant trend toward a reduced rate of institution-
alization (10% placebo vs 5% donepezil) offset the effects 
increased drug costs.
Subsequently, the effects of donepezil on the costs of 
AD in a managed care organization were examined in a two-
year study (Fillit et al 1999). Costs attributable to medical 
care and prescriptions were assessed in 70 individuals with 
dementia before and after they were prescribed donepezil. 
Although treatment was associated with decreased costs of 
medical care, overall costs were increased by ∼US$2.11/day, 
attributable to the cost of prescription medications.
Hill and colleagues (2002) examined health care costs in 
204 patients with AD and related dementias who were receiv-
ing donepezil and 204 matched controls. After controlling for 
age, sex, comorbid conditions, pharmacy beneﬁ  t status, and 
complications of dementia, mean costs per year of medical 
services and prescription drugs were found to be ~US$3900 
lower in the donepezil group. Reduced expenditures were 
most apparent in lower use of inpatient hospital and postacute 
skilled nursing facility (SNF) services, but were partially 
offset by the higher prescription-drug costs in donepezil-
treated patients. Briefer treatment duration (9 months) was 
associated with lesser beneﬁ  t (∼US$3600).
Another managed care study examined costs in 1366 
patients with AD and related disorders and 13660 controls 
(Fillit et al 2002). Among more mildly impaired AD patients, 
35% received a cholinesterase inhibitor drug (donepezil in 
all but one patient). Use of a cholinesterase inhibitor was 
associated with an annualized cost savings of US$2408. 
Unfortunately, no statistical analysis of this ﬁ  gure is reported, 
so its meaningfulness can not be interpreted.Neuropsychiatric Disease and Treatment 2008:4(3) 553
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More recently, healthcare costs in association with 
donepezil were assessed in a managed Medicare setting (Lu 
et al 2005). Cost data from 229 donepezil-treated patients 
were compared with data from 458 dementia patients who 
had never been treated using a regression analysis to esti-
mate the impact of donepezil treatment on healthcare costs 
and utilization over one year of follow up. The groups were 
matched for age, sex, number of comorbid conditions, and 
complications of severe dementia. The mean costs of medical 
services per year in the donepezil group were ∼US$2500 less 
than those in the control group. Signiﬁ  cantly lower hospital 
and skilled nursing facility costs in the treated group were 
partially offset by US$1241 higher costs associated with 
higher prescription medication, physician ofﬁ  ce and out-
patient hospital expenditures. Patients receiving donepezil 
had less use of much more expensive inpatient services and 
a higher number of physician's ofﬁ  ce visits (11 vs 8 visits) 
compared with controls, suggesting a more cost-effective use 
of healthcare resources in the treated group. Caution is war-
ranted in interpreting these case-control ﬁ  ndings, however, 
since the social and family environment of patients receiving 
prescription medication for dementia is likely to differ from 
those not being similarly treated, and the cost effects may 
simply be correlates of overall family function.
Modeling studies of cost-
effectiveness
Space precludes a detailed review of all claims of cost-beneﬁ  t 
related to treatment with antidementia drugs based on eco-
nomic modeling, but there are common themes among them. 
Most have been sponsored by manufacturers of therapeutic 
agents and most have reported positive results, which raises 
the possibility of publication bias in the available studies. 
Prior to the emergence of prospective pharmacoeconomic 
data since 2003, economic implications of AD therapies 
were typically imputed on the basis increased direct costs 
of care associated with higher levels of severity. Some older 
economic models did not identify higher total costs of care 
in more severely affected patients, as it appeared that costs 
shifted from being informal and caregiver-borne, to formal 
and institutionally-borne. However, more recent data sug-
gests dramatic increases in both direct and indirect costs with 
disease progression (Langa et al 2001; Zhu et al 2006).
Assumptions about costs of care as they relate to measures 
of severity have been generated by analysis of caregiver 
reported service use in small samples. Among the most 
commonly cited is the study by Ernst and colleagues (1997), 
which used a cohort of 64 patients to estimate costs associated 
with speciﬁ  c cognitive test scores and used that information 
to predict the economic consequences of maintaining or 
improving cognition. The predicted economic impact of a 
theoretical treatment was greatest in the moderately impaired 
patients, rather than mild or end-stage patients. The report 
provides an example of a person with a MMSE of 7; if 
treatment could prevent cognitive decline for 1 year, cost 
savings would be ∼US$3700 (in 1997 dollars). Sustaining 
a two point increase in MMSE in the same patient would 
predict an annual cost savings of ∼US$7100 (Ernst et al 
1997). Subsequent studies have mapped cognitive results 
from double-blind placebo-controlled trials of anti-dementia 
drugs onto this model to estimate cost-savings with avail-
able therapeutic agents (Hauber et al 2000). More recent 
studies suggest that daily function is a better predictor of 
costs than cognition (Wolstenholme et al 2002; Zhu 2006). 
Numerous studies of cholinesterase inhibitors and memantine 
have shown relative preservation of functional capacity in 
comparison to placebo, which might be predicted to reduce 
costs. However, among studies with statistically signiﬁ  cant 
advantages on functional ratings among the treated cohort, 
prospectively collected pharmacoeconomic data have not 
shown predicted levels of direct cost savings (Wimo et al 
2003a, 2003b; AD2000 2004; Feldman et al 2004).
Another common approach to modeling cost savings 
with treatment is the use of statistical models that estimate 
costs avoided by delaying transition to more severe levels of 
impairment or dependency (Stewart et al 1998; Ward et al 
2003; Jones et al 2004). These approaches are supported 
by a double-blind placebo controlled trial of donepezil that 
showed a higher likelihood of maintaining daily function in 
the treated group over one year (Mohs et al 2000), but is not 
supported by the AD2000 trial, which showed no effect of 
donepezil treatment on time to increased disability (AD2000 
2004). A key issue in the interpretation of the economics 
associated with “delayed-transition” models is whether the 
patient is dependent, ie, requires full time care, while residing 
in community settings. If all patients residing in community 
settings are considered “nondependent,” as was done in 
formulating policy on payment for antidementia drugs in 
the UK, then the potential to discern economic effects of 
treatment is minimized (Neumann et al 2005). Clearly, better 
consensus on deﬁ  ning dependency in dementia and associ-
ated health utility estimates that inﬂ  uence the calculation of 
QALYs is required.
A relatively understudied component of the economic con-
sequences of the antidementia drugs is their impact on behav-
ioral disturbances intrinsic to the disease. Behavioral symptoms Neuropsychiatric Disease and Treatment 2008:4(3) 554
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like agitation, aggression, and psychosis are major drivers of 
cost in community dwelling dementia patients (Herrmann et al 
2006), as well as a critical factor in the economically important 
decision to institutionalize. While there are indications that 
cholinesterase inhibitors can reduce, or delay the emergence 
of behavioral symptoms, either alone (Trinh et al 2003) or in 
conjunction with memantine (Cummings et al 2006), no cost-
beneﬁ  t analyses of this effect appear to have been published.
In summary, modeling studies generally support the poten-
tial for cost-effectiveness of existing antidementia therapies. 
However, their underlying assumptions may not be accurate for 
the treated population. More research is required to understand 
how they can be effectively and objectively applied, and whether 
they will better map onto prospectively observed outcomes.
Summary
Numerous studies employing different methodologies have 
been undertaken to explore the potential value of antide-
mentia therapies. Despite their common use in many coun-
tries, deﬁ  nitive evidence of cost beneﬁ  ts has not emerged. 
The calculation of health utilities, which determine cost-
effectiveness, remains fraught with lack of consensus and 
idiosyncratic interpretations of existing data (Neumann 
2005). Furthermore, in the absence of a better understanding 
of how to measure quality of life issues among people with 
dementia and their caregivers, the theoretical basis of QALY-
based measurements is doubtful in this patient population.
Prospective trials suggest but do not conﬁ  rm beneﬁ  ts 
at the family and societal levels and argue against direct 
individual cost beneﬁ  ts to the patient. In contrast, popula-
tion based studies suggest reduced costs of care to insurers 
among patients treated with cholinesterase inhibitors. It is 
likely that family and social factors predisposing to better 
overall care contribute to positive outcomes observed in 
the managed care settings. Published studies that model 
costs and savings tend to appear the most favorable toward 
antidementia treatments, but are subject to several levels of 
bias in design, interpretation, and publication. The current 
state of the available data is perhaps best summarized by 
the Cochrane Library review of cholinesterase inhibitors 
for dementia, which states that, “it would be inappropriate 
for any provider of healthcare to make a decision regarding 
the availability of (antidementia drugs) for patients based on 
these economic models (Birks 2006).
Practical considerations
There is a troubling undertone in discussions about cost and 
effectiveness regarding treatments for AD. Advocates and 
critics alike seem to ignore the roles of the patient/family 
unit and the physician in the decision-making process 
regarding whether treatment is providing a meaningful 
beneﬁ  t. It is inappropriate to make treatment decisions in 
the clinical setting on the “treat all” vs “treat none” (Clarke 
2004) dichotomy implied by the question, “Are antidementia 
therapies cost-effective?”
Existing data indicate that families are able to identify 
and report individualized goals for dementia intervention 
(Rockwood et al 2002) and that physicians acknowledge 
that there are treatment outcomes not detected by standard 
instruments (Rockwood et al 2004). In light of this, and the 
fact that most patients seek care for symptomatic illnesses to 
relieve suffering rather than reduce costs, it seems appropri-
ate to make individualized treatment decisions based on the 
patient/family’s needs and goals, and monitor the success of 
treatment in achieving them. If treatment creates intolerable 
adverse effects, or fails to deliver satisfactory levels of efﬁ  cacy, 
discontinuation would be warranted (and likely cost-effective). 
In contrast, if the patient is doing discernibly well, relative to 
expectation, and the family is satisﬁ  ed with the situation, then 
continuing the therapy would seem appropriate on clinical 
grounds alone. AD is a devastating and depersonalizing ill-
ness, and there is reasonable evidence available that treatment 
can blunt its effects in many patients. At the current state of 
knowledge, careful clinical decision-making in collaboration 
with the patient and family – rather than isolated consideration 
of murky economic factors – appears to be the most prudent 
and compassionate course of action to determine treatment 
strategies for the patient with dementia.
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